Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature
| Autor: | H.P. Xu, Paul Cottu, Youlia M. Kirova, A. Beddok, Baptiste Porte, Alain Fourquet, Alexandre Arsene Henry |
|---|---|
| Přispěvatelé: | Institut Curie [Paris], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ) |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Neutropenia Pyridines medicine.medical_treatment [SDV.CAN]Life Sciences [q-bio]/Cancer Breast Neoplasms Palbociclib Brief Communication Piperazines 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Medicine Radiodermatitis Humans Neoplasm Metastasis Protein Kinase Inhibitors Retrospective Studies business.industry Cancer Cyclin-Dependent Kinase 4 Chemoradiotherapy Cyclin-Dependent Kinase 6 medicine.disease Dysphagia 3. Good health Radiation therapy 030220 oncology & carcinogenesis Concomitant Female medicine.symptom business Febrile neutropenia |
| Zdroj: | British Journal of Cancer British Journal of Cancer, Cancer Research UK, 2020, 123 (6), pp.905-908. ⟨10.1038/s41416-020-0957-9⟩ |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/s41416-020-0957-9⟩ |
| Popis: | Palbociclib in combination with endocrine therapy increases progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer (BC). In this study, we retrospectively evaluated safety in the first patient treated with concurrent use of palbociclib and radiation therapy (RT) in the Curie Institute. Between April 2017 and August 2019, 30 women with metastatic BC received locoregional and/or symptomatic irradiation at a metastatic site concurrently with palbociclib. The most common acute toxicities were radiodermatitis and neutropenia. Palbociclib had to be discontinued during RT in three locally treated patients who developed grade 3 radiodermatitis and febrile neutropenia, grade 2 dysphagia and metastatic disease progression, respectively. After a follow-up of at least 6 months, none of the patients had late toxicity. Concomitant administration of palbociclib with RT was reasonably well tolerated in our series of 30 patients. More prospective data with longer follow-up are needed to confirm these results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink